Amylin, Eli Lilly and Alkermes Say Diabetic Drug Meets Trial Goal
Posted on: Thursday, 1 November 2007, 15:00 CDT
Amylin Pharmaceuticals, Eli Lilly and Alkermes have announced positive results from a 30-week comparator study of their once-weekly exenatide long-acting release injection and Byetta injection taken twice-daily in patients with type 2 diabetes.
The 30-week, open-label, noninferiority study included 295 subjects with type 2 diabetes who were not achieving adequate glucose control using diet and exercise with or without the use of one or more oral anti-diabetic agents.
Once-weekly exenatide, a long-acting version of Amylin's diabetes drug Byetta, showed a statistically significant improvement in A1C of approximately 1.9% from baseline, compared to an improvement of approximately 1.5% for Byetta. Approximately three out of four subjects treated with once-weekly exenatide achieved an A1C of 7%, which is the target for good glucose control as recommended by the American Diabetes Association.
After 30 weeks of treatment, both once-weekly exenatide and Byetta resulted in an average weight loss of approximately eight pounds. The companies anticipate a regulatory submission to the FDA by the end of the first half of 2009.
Source: Datamonitor
Related Articles
- FDA Approval Sought For Once-Weekly Diabetes Treatment
- Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
- After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
- Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
- Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
- Roche Gains EU Approval for Once Weekly NeoRecormon
- Higher Persistency Rates Seen With FOSAMAX(R) Once Weekly Therapies Compared to Other Weekly and Monthly Oral Bisphosphonates, According to Two New Outcomes Studies
- Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control; Preliminary Results From Phase 2 Study Announced
- Merck Comments on Court of Appeals' Decision for Merck's Once-Weekly FOSAMAX Patent
- Smokers Not Concerned About Developing 4th Leading Cause of Death; Yet More Than Half Have Symptoms Once a Week
 |
 |
User Comments (0)
RSS Feeds